Vaccine allergies

Chung, Eun Hee

doi:10.7774/cevr.2014.3.1.50

Cited by 118 publications

(130 citation statements)

References 34 publications

(45 reference statements)

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…In some of these cases, autoimmunity is suspected to result from molecular mimicry in which antigens of the pathogen resemble host epitopes (31)(32)(33). Thus, avoiding potentially detrimental cross-reactive responses is a high priority when developing new vaccines (32)(33)(34)(35).…”

Section: Discussionmentioning

confidence: 99%

Immunizations with Enterotoxigenic Escherichia coli Heat-Stable Toxin Conjugates Engender Toxin-Neutralizing Antibodies in Mice That Also Cross-React with Guanylin and Uroguanylin

et al. 2019

View full text Add to dashboard Cite

Infection with enterotoxigenic Escherichia coli (ETEC) is a common cause of childhood diarrhea in low-and middle-income countries, as well as of diarrhea among travelers to these countries. In children, ETEC strains secreting the heatstable toxin (ST) are the most pathogenic, and there are ongoing efforts to develop vaccines that target ST. One important challenge for ST vaccine development is to construct immunogens that do not elicit antibodies that cross-react with guanylin and uroguanylin, which are endogenous peptides involved in regulating the activity of the guanylate cyclase-C (GC-C) receptor. We immunized mice with both human ST (STh) and porcine ST (STp) chemically coupled to bovine serum albumin, and the resulting sera neutralized the toxic activities of both STh and STp. This suggests that a vaccine based on either ST variant can confer cross-protection. However, several anti-STh and anti-STp sera cross-reacted with the endogenous peptides, suggesting that the ST sequence must be altered to reduce the risk of unwanted crossreactivity. Epitope mapping of four monoclonal anti-STh and six anti-STp antibodies, all of which neutralized both STh and STp, revealed that most epitopes appear to have at least one amino acid residue shared with guanylin or uroguanylin. Despite this, only one monoclonal antibody displayed demonstrable cross-reactivity to the endogenous peptides, suggesting that targeted mutations of a limited number of ST residues may be sufficient to obtain a safe ST-based vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunizations with Enterotoxigenic Escherichia coli Heat-Stable Toxin Conjugates Engender Toxin-Neutralizing Antibodies in Mice That Also Cross-React with Guanylin and Uroguanylin

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Allergencity is an important factor in vaccine design as allergic reaction could be fatal to the patients and hence we tested the allergencity of our proposed vaccine using allertop software which confirm the non allergencity of the vaccine. (62) Furthermore the antigenicity is a significant factor to tack into account when choosing a target for vaccine design, (63) therefore we tested the antigenicity of mhc1 and mhc2 peptide using vaxiJen software which shows 4 peptides to be antigenic in mhc1(YLYRYGYTR, WRFDVKAQM, LIADKWPAL, MYPMYRFTE) and one peptide to be antigenic in mhc2 (RRLWRFDVKAQMVD). (Table 7)…”

Section: Discussionmentioning

confidence: 99%

Immunoinformatic design of multi epitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target

Abdelmoneim

Mustafa

Abdelmageed

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cancer remains a major public health hazard despite the extensive research over the years on cancer diagnostic and treatment , this is mainly due to the complex pathophysiology and genetic makeup of cancer. A new approach toward cancer treatment is the use of cancer vaccine, yet the different molecular bases of cancers reduce the effectiveness of this approach. In this work we aim to use matrix metalloproteinase-9 protein (MMP9) which is essential molecule in the survival and metastasis of all type of cancer as a target for universal cancer vaccine design. Method: reference sequence of matrix metalloproteinase-9 protein was obtained from NCBI databases along with the related sequence, which is then checked for conservation using BioEdit, furthermore the B cell and T cell related peptide were analyzed using IEDB website. The best candidate peptide were then visualized using chimera software. Result: Three Peptides found to be good candidate for interactions with B cells (SLPE, RLYT, and PALPR), while ten peptides found as a good target for interactions with MHC1 (YRYGYTRVA, YGYTRVAEM, YLYRYGYTR, WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR , MYPMYRFTE, FLIADKWPA) with world combined coverage of 94.77% . In addition, ten peptides were also found as a good candidates for interactions with MHC2 (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS), with world combined coverage of 90.67%. CONCLUSION: 23 peptide-based vaccine was designed for use as a universal cancer vaccine which has a high world population coverage for MHC1(94.77%) and MHC2 (90.67%) related alleles. Introduction:Cancer is a chronic disease with varying degree of manifestations characterized by abnormal cell division and high mortality and morbidity rates, in addition it is considered the second leading cause of death worldwide with an estimated 8 million death annually and 18 million new case per year.(1-5) although cancer survival rate increased dramatically over the years in many countries, yet more work are needed to improve the prognosis of patients suffering from this depilating disease.(6, 7) Cancer can be either common or rare depending on the number of cases. Usually any cancer with a number of cases below 6 in 100000 annually is considered rare type.(8) All types of cancers cause common clinical symptoms including weight-loss, fatigue, pain, nausea, vomiting and constipation, etc.(9)Additional symptoms are specific to the site of malignancy.(10) Breast cancer is the most common site of cancer in women worldwide.(11) Lung cancer is the second most common cancer in both men and women while colorectal is the third most common type cancer in both sexes. (12) The classical management for cancer composed of chemotherapy, radiotherapy and surgery. Recently Immunotherapy started to shows very promising result in field of cancer management. Different type of immunotherapy are available including cytokine therapy, ...

show abstract

“…Although vaccination is an efficient method to prevent the diseases, the potential risk of allergic reactions exists. These allergic reactions are mediated by the reaction of IgE antibody with a vaccine itself or the vaccine components (77)(78)(79). Thus, our predicted B and T cell epitopes were subjected to allergenicity test using AllerTopv.2.0.…”

Section: Discussionmentioning

confidence: 99%

Translationally Controlled Tumor ProteinTCTPas Peptide Vaccine againstSchistosoma japonicum: an Immunoinformatics Approach

Abdalrahman¹,

Ahmed²,

Elnaeem³

et al. 2018

Preprint

View full text Add to dashboard Cite

Schistosoma japonicum is the most pathogenic causative form of schistosomiasis that causes a major health problem in its endemic countries. Until now, praziquantel is the only drug used to treat Schistosomiasis, but it does not prevent re-infection. So, repetition of the treatment is needed. Moreover, there is no effective vaccine against S. japonicum. Therefore, an urgent need for the development of vaccines is mandatory. This study aimed to analyze an immunogenic protein, Transitionally Controlled Tumor Protein (TCTP) using an immunoinformatics approach to design a universal peptide vaccine against Schistosoma japonicum. A set of 22 of TCTP sequences were retrieved from NCBI database. Conservancy of these sequences was tested and then conserved B cell and T cell epitopes were predicted using different tools available in IEBD. Epitopes having high scores in both B and T cell predicting tools were proposed. An epitope 129 YEHYI 133 was predicted as a most promising epitope with good prediction scores in surface accessibility and antigenicity. Besides that, epitopes 129 YEHYIGESM 137 and 92 YLKAIKERL 100 were predicted as the most promising epitopes concerning their binding to MHC I and MHC II allele respectively. The study revealed that our predicted epitopes could be used to develop an efficacious vaccine against Schistosoma japonicum in the future especially epitope YEHYIGESM as it is shared between MHC I and II alleles and overlapped with the most promising B cell epitope. Both in vitro and in vivo studies is recommended to confirm the efficacy of YEHYIGESM as a peptide vaccine.

show abstract

Vaccine allergies

Cited by 118 publications

References 34 publications

Immunizations with Enterotoxigenic Escherichia coli Heat-Stable Toxin Conjugates Engender Toxin-Neutralizing Antibodies in Mice That Also Cross-React with Guanylin and Uroguanylin

Immunizations with Enterotoxigenic Escherichia coli Heat-Stable Toxin Conjugates Engender Toxin-Neutralizing Antibodies in Mice That Also Cross-React with Guanylin and Uroguanylin

Immunoinformatic design of multi epitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target

Translationally Controlled Tumor ProteinTCTPas Peptide Vaccine againstSchistosoma japonicum: an Immunoinformatics Approach

Contact Info

Product

Resources

About